Asian Currencies Steady as Rupee Hits Record Low Amid Fed Rate Cut Bets 
RBI Cuts Repo Rate to 5.25% as Inflation Cools and Growth Outlook Strengthens 
Anthropic Reportedly Taps Wilson Sonsini as It Prepares for a Potential 2026 IPO 
Netflix Nearing Major Deal to Acquire Warner Bros Discovery Assets 
IMF Deputy Dan Katz Visits China as Key Economic Review Nears 
Japan’s Nikkei Drops as Markets Await Key U.S. Inflation Data 
Asian Markets Mixed as Fed Rate Cut Bets Grow and Japan’s Nikkei Leads Gains 
China Urged to Prioritize Economy Over Territorial Ambitions, Says Taiwan’s President Lai 
Dollar Slides to Five-Week Low as Asian Stocks Struggle and Markets Bet on Fed Rate Cut 
Wikipedia Pushes for AI Licensing Deals as Jimmy Wales Calls for Fair Compensation 
Fed Meeting Sparks Division as Markets Brace for Possible Rate Cut 
Asia’s IPO Market Set for Strong Growth as China and India Drive Investor Diversification 
OpenAI Moves to Acquire Neptune as It Expands AI Training Capabilities 
Momenta Quietly Moves Toward Hong Kong IPO Amid Rising China-U.S. Tensions 
Europe Confronts Rising Competitive Pressure as China Accelerates Export-Led Growth 
Vietnam’s November Trade Sees Monthly Decline but Strong Year-on-Year Growth 
Lotte Biologics has inked a memorandum of understanding (MOU) with Roche Diagnostics to bolster its Contract Development and Manufacturing Organization (CDMO) capabilities. This collaboration signifies major diagnostics, hardware, and automation advancements for Lotte's upcoming Korean production plants.
On Wednesday, Aug. 9, Lotte Biologics said it will work with Roche Diagnostics to improve the productivity and quality of its productions. The company said they would also team up to establish hardware and automation systems for Lotte's upcoming production plants in Korea, as per Korea Joongang Daily.
The MOU was signed at Roche Diagnostics CustomBiotech Center in Penzberg, Germany. Lotte Biologics' chief executive officer, Richard Lee; Roche Diagnostics CustomBiotech's vice president, Rainer Mueller; and Roche Diagnostics Korea's general manager, Kit Tang, were all present at the signing ceremony.
With the deal in place, Lotte Biologics aims to amplify its credibility with future global clients. The agreement will also serve as the forefront to underpin and shore up Roche Diagnostics' supply network in the Asian market. This will also give better treatment access to patients around the world.
"Through this MOU, we plan to enhance the production process capabilities of our Korean Mega Plant in collaboration with Roche Diagnostics," Lotte Biologics chief Richard Lee said in a press release. "Through synergy with Roche Diagnostics, an industry leader in the in vitro diagnostic field, LOTTE hopes to improve the efficiency of its operations at the forthcoming Korean Mega Plant, simultaneously augmenting the quality of our manufacturing and fulfilling customer needs."
Finally, Business Korea reported that Lotte Biologics and Roche Diagnostics will cooperate on various business fronts, including installing automation systems at the former's Mega Plants that will be built in Korea. The latter will also provide technical consulting and equipment support for the facilities.
Photo by: Lotte Biologics Newsroom
